Stockreport
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER [TheStreet.com]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PR Newswire THOUSAND OAKS, Calif., April 22, 2026 Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif. April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026. Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities. As inaugural chief technology officer, Reese encouraged the early adoption of technology and artificial intelligence across all facets of the business, in particular R&D. "Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Am
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings [Yahoo! Finance][Yahoo! Finance]
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER[PR Newswire]
- USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS™ CDR-Scanning [Yahoo! Finance][Yahoo! Finance]
- What to Expect From Amgen's Next Quarterly Earnings Report [Yahoo! Finance][Yahoo! Finance]
- Amgen (AMGN) was given a new $366.00 price target by Canaccord Genuity Group Inc..[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 4/22/26 - Form 8-K
- 4/21/26 - Form DEFA14A
- 4/15/26 - Form DEFA14A
- AMGN's page on the SEC website
- More